Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Purity: ≥98%
Peramivir Trihydrate (also known as BCX-1812, RWJ-270201, S-021812; trade name Rapivab) is a trihydrate form of the antiviral agent peramivir which is a transition-state analogue and a specific influenza viral neuraminidase inhibitor approved for the treatment of influenza. It inhibits with neuraminidase an IC50 of median 0.09 nM. Peramivir protects mice against severe disease outcomes following infection with highly pathogenic avian influenza and multi-dose treatment was efficacious in ferrets. Peramivir combined with Oseltamivir perform better than suboptimal doses of each compound alone to treat influenza infections in mice. Peramivir (30 mg/kg) is effective in promoting the survival of mice infected with systemically replicating H5N1 virus.
ln Vitro |
|
||
---|---|---|---|
ln Vivo |
|
||
Animal Protocol |
|
||
References |
Virology.2008 Apr 25;374(1):198-209;Antiviral Res.2010 Oct;88(1):38-44;Antiviral Res.2008 Nov;80(2):150-7.
|
Molecular Formula |
C15H28N4O4.3H2O
|
---|---|
Molecular Weight |
382.45
|
Elemental Analysis |
C, 47.11; H, 8.96; N, 14.65; O, 29.28
|
CAS # |
1041434-82-5
|
Related CAS # |
Peramivir;330600-85-6
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
O[C@H]1[C@]([C@H](C(CC)CC)NC(C)=O)([H])[C@H](NC(N)=N)C[C@@H]1C(O)=O.[H]O.[H]O.[H]O
|
InChi Key |
RFUCJKFZFXNIGB-ZBBHRWOZSA-N
|
InChi Code |
InChI=1S/C15H28N4O4.3H2O/c1-4-8(5-2)12(18-7(3)20)11-10(19-15(16)17)6-9(13(11)21)14(22)23;;;/h8-13,21H,4-6H2,1-3H3,(H,18,20)(H,22,23)(H4,16,17,19);3*1H2/t9-,10+,11+,12-,13+;;;/m0.../s1
|
Chemical Name |
(1S,2S,3R,4R)-3-((S)-1-acetamido-2-ethylbutyl)-4-guanidino-2-hydroxycyclopentanecarboxylic acid trihydrate
|
Synonyms |
BCX-1812,RWJ-270201, S-021812; BCX1812; BCX 1812; RWJ 270201; RWJ270201; Peramivir. Brand name: Rapivab; Rapiacta and Peramiflu
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
5%TFA : ~3 mg/mL
H2O : ~5 mg/mL (~13.07 mM) DMSO : ~0.2 mg/mL ( ~0.52 mM) |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 4.55 mg/mL (11.90 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication (<60°C).
 (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.6147 mL | 13.0736 mL | 26.1472 mL | |
5 mM | 0.5229 mL | 2.6147 mL | 5.2294 mL | |
10 mM | 0.2615 mL | 1.3074 mL | 2.6147 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.